Why is Indoco Remedies Ltd falling/rising?

Intraday Performance and Market Activity

Indoco Remedies Ltd's stock surged by Rs 11.80, marking a 5.61% rise as of 08:20 PM on 27-Jan. This gain was accompanied by an intraday high of Rs 222, reflecting strong buying momentum during the trading session. The stock outperformed its sector by 5.94%, signalling relative strength in a volatile market environment. Intraday volatility was elevated at 5.28%, indicating significant price fluctuations throughout the day. Notably, the weighted average price suggested that a larger volume of shares traded closer to the lower end of the price range, hinting at some profit-taking or cautious trading despite the overall upward movement.

Investor participation has been on the rise, with delivery volume on 23 Jan reaching 27,300 shares, a 37.58% increase compared to the five-day average. This uptick in delivery volume suggests growing conviction among investors to hold the stock rather than engage in short-term trading. Liquidity remains adequate, supporting trade sizes of approximately Rs 0.01 crore, which facilitates smoother transactions for market participants.

Long-Term Performance and Benchmark Comparison

Despite the recent price uptick, Indoco Remedies has struggled over longer time horizons. Over the past year, the stock has declined by 13.82%, significantly underperforming the Sensex, which gained 8.61% during the same period. The underperformance extends further back, with the stock falling 34.41% over three years and 30.69% over five years, while the Sensex posted gains of 37.97% and 72.66% respectively. This persistent lag highlights structural challenges within the company and its sector.

Year-to-date, the stock has declined 5.45%, slightly worse than the Sensex's 3.95% fall, although it has outperformed the benchmark in the past week with a 6.71% gain compared to the Sensex's marginal 0.39% decline. This short-term resilience may reflect tactical buying or speculative interest rather than a fundamental turnaround.

Financial Health and Profitability Concerns

Indoco Remedies faces significant financial headwinds that temper enthusiasm around its recent price rise. The company exhibits a high Debt to EBITDA ratio of 4.18 times, indicating a strained ability to service its debt obligations. This is compounded by a debt-equity ratio of 1.02 times as of the half-year mark, signalling elevated leverage levels that increase financial risk.

Profitability metrics remain weak, with an average Return on Equity of just 9.06%, reflecting limited efficiency in generating shareholder returns. Operating profits have deteriorated sharply, declining at an annualised rate of 185.53% over the last five years. The company has reported negative results for 12 consecutive quarters, underscoring persistent operational challenges.

Interest expenses have surged by 48.67% in the latest six-month period to Rs 50.68 crore, further pressuring earnings. Return on Capital Employed (ROCE) stands at a negative 2.14%, highlighting the company's inability to generate adequate returns on invested capital. These factors collectively contribute to the stock's classification as risky, with profits falling by 552.7% over the past year despite the recent price rally.

Investor Sentiment and Institutional Participation

Institutional investors have reduced their stake by 0.77% in the previous quarter, now holding 19.41% of the company’s shares. This decline in institutional participation may reflect concerns over the company’s fundamentals and long-term prospects. Institutional investors typically possess greater analytical resources and tend to adjust holdings based on fundamental assessments, so their reduced involvement signals caution.

Moreover, the stock has consistently underperformed the BSE500 index over the last three annual periods, reinforcing the narrative of underwhelming performance relative to broader market benchmarks. While the recent price rise on 27-Jan indicates some renewed interest, it remains to be seen whether this momentum can be sustained amid the company’s ongoing financial and operational challenges.

Conclusion

Indoco Remedies Ltd’s 5.61% price increase on 27-Jan reflects a short-term rebound driven by increased investor participation and relative outperformance against its sector. However, the company’s weak financial health, persistent negative operating results, and long-term underperformance against benchmarks temper optimism. Elevated debt levels, declining profitability, and reduced institutional interest suggest that the stock remains a risky proposition despite the recent rally. Investors should weigh these factors carefully when considering exposure to Indoco Remedies.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →